Skip to main content

Compare Stocks

Date Range: 

 LogicBio TherapeuticsGenfitGamida CellProtara TherapeuticsINmune Bio
SymbolNASDAQ:LOGCNASDAQ:GNFTNASDAQ:GMDANASDAQ:TARANASDAQ:INMB
Price Information
Current Price$4.72$4.25$6.32$9.31$10.05
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.31.41.81.5
Analysis Score3.53.33.53.53.5
Community Score2.42.72.72.63.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.02.50.8
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$18.50$51.00$20.25$44.00$21.20
% Upside from Price Target291.95% upside1,100.00% upside220.41% upside372.61% upside110.95% upside
Trade Information
Market Cap$152.44 million$186.99 million$157.19 million$101.17 million$146.05 million
Beta1.341.332.031.173.01
Average Volume132,264180,950774,568121,886264,218
Sales & Book Value
Annual RevenueN/A$45.88 millionN/AN/AN/A
Price / SalesN/A4.24N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.84 per share$2.49 per share$1.44 per share($21.67) per share$2.19 per share
Price / BookN/A1.71N/AN/AN/A
Profitability
Net Income$-40,130,000.00$-72,960,000.00$-34,350,000.00$-14,990,000.00$-7,680,000.00
EPS($1.78)($1.97)($1.69)N/A($0.75)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-117.64%N/A-112.47%-45.45%-41.18%
Return on Assets (ROA)-76.85%N/A-65.09%-41.09%-39.34%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.40%5.74%N/AN/AN/A
Current Ratio6.21%5.71%5.39%42.99%17.73%
Quick Ratio6.21%5.71%5.39%42.99%17.73%
Ownership Information
Institutional Ownership Percentage33.78%0.41%N/A83.11%7.38%
Insider Ownership Percentage23.40%N/AN/A45.70%58.87%
Miscellaneous
Employees39203110274
Shares Outstanding32.16 million45.78 million24.22 million11.23 million14.93 million
Next Earnings Date8/9/2021 (Estimated)7/1/2021 (Estimated)8/10/2021 (Estimated)7/30/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Buy" by AnalystsINmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - May 16 at 4:36 AM
INmune Bio, Inc. (NASDAQ:INMB) Expected to Announce Earnings of -$0.33 Per ShareINmune Bio, Inc. (NASDAQ:INMB) Expected to Announce Earnings of -$0.33 Per Share
americanbankingnews.com - May 13 at 9:58 AM
INmune Bio, Inc. (INMB) CEO RJ Tesi on Q1 2021 Results - Earnings Call TranscriptINmune Bio, Inc. (INMB) CEO RJ Tesi on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 8:03 PM
INmune Bio (NASDAQ:INMB) Releases Quarterly  Earnings Results, Misses Estimates By $0.05 EPSINmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS
americanbankingnews.com - May 7 at 3:46 PM
INmune Bio, Inc. (INMB) Q1 2021 Earnings Call TranscriptINmune Bio, Inc. (INMB) Q1 2021 Earnings Call Transcript
fool.com - May 6 at 4:34 AM
INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business UpdateINmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update
finance.yahoo.com - May 5 at 5:45 PM
INmune Bio (INMB) Scheduled to Post Earnings on WednesdayINmune Bio (INMB) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 29 at 8:16 AM
INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update ...INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update ...
apnews.com - April 28 at 12:28 PM
INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5
finance.yahoo.com - April 28 at 12:28 PM
INmune Bio (NASDAQ:INMB) Now Covered by Analysts at B. RileyINmune Bio (NASDAQ:INMB) Now Covered by Analysts at B. Riley
americanbankingnews.com - April 27 at 9:12 AM
What Type Of Shareholders Make Up INmune Bio, Inc.s (NASDAQ:INMB) Share Registry?What Type Of Shareholders Make Up INmune Bio, Inc.'s (NASDAQ:INMB) Share Registry?
finance.yahoo.com - April 26 at 10:03 AM
INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences ConferenceINmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference
finance.yahoo.com - April 26 at 10:03 AM
Zacks: Analysts Expect INmune Bio, Inc. (NASDAQ:INMB) to Post -$0.28 Earnings Per ShareZacks: Analysts Expect INmune Bio, Inc. (NASDAQ:INMB) to Post -$0.28 Earnings Per Share
americanbankingnews.com - April 25 at 2:06 PM
Research Analysts Offer Predictions for INmune Bio, Inc.s Q1 2021 Earnings (NASDAQ:INMB)Research Analysts Offer Predictions for INmune Bio, Inc.'s Q1 2021 Earnings (NASDAQ:INMB)
americanbankingnews.com - April 23 at 6:36 AM
Why INmune Bio, Inc. (NASDAQ:INMB) Stock Might Be A Good InvestmentWhy INmune Bio, Inc. (NASDAQ:INMB) Stock Might Be A Good Investment
stocksregister.com - April 18 at 7:56 AM
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two ...INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two ...
apnews.com - March 23 at 9:25 AM
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical MeetingsINmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings
finance.yahoo.com - March 22 at 9:48 AM
INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
finance.yahoo.com - March 8 at 9:50 AM
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business UpdateINmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
finance.yahoo.com - March 4 at 7:55 PM
INmune Bio, Inc. to Host Earnings CallINmune Bio, Inc. to Host Earnings Call
finance.yahoo.com - March 4 at 2:55 PM
INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
finance.yahoo.com - February 25 at 12:57 PM
We Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business GrowthWe Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business Growth
finance.yahoo.com - January 25 at 8:51 AM
Why INmune Bio Stock Soared Then Sank TodayWhy INmune Bio Stock Soared Then Sank Today
finance.yahoo.com - January 23 at 10:47 PM
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration ...INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration ...
apnews.com - January 21 at 8:08 AM
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b TrialINmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
finance.yahoo.com - January 21 at 8:08 AM
DateCompanyBrokerageAction
3/10/2021LogicBio TherapeuticsJMP SecuritiesInitiated Coverage
3/1/2021LogicBio TherapeuticsWilliam BlairReiterated Rating
5/22/2020LogicBio TherapeuticsChardan CapitalReiterated Rating
5/1/2019LogicBio TherapeuticsRoth CapitalInitiated Coverage
11/13/2018LogicBio TherapeuticsBarclaysInitiated Coverage
4/5/2021GenfitSVB LeerinkLower Price Target
2/12/2021GenfitBryan, Garnier & CoUpgrade
11/16/2020GenfitHC WainwrightReiterated Rating
7/23/2020GenfitStifel NicolausUpgrade
6/25/2020GenfitBank of AmericaInitiated Coverage
5/22/2020GenfitB. RileyBoost Price Target
5/13/2020GenfitKepler Capital MarketsDowngrade
5/12/2020GenfitOddo BhfDowngrade
3/15/2021Gamida CellNeedham & Company LLCLower Price Target
3/9/2021Gamida CellPiper SandlerLower Price Target
2/9/2021Gamida CellOppenheimerReiterated Rating
6/30/2020Gamida CellEvercore ISIInitiated Coverage
2/26/2020Gamida CellBMO Capital MarketsLower Price Target
11/21/2018Gamida CellCIBCInitiated Coverage
10/19/2020Protara TherapeuticsCowenInitiated Coverage
7/29/2020Protara TherapeuticsGuggenheimInitiated Coverage
1/22/2020Protara TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
2/9/2021INmune BioMaxim GroupReiterated Rating
9/1/2020INmune BioBTIG ResearchInitiated Coverage
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.